Q2 FY2026 EarningsQ2 FY2026 results showed a significant revenue miss ($0.76M vs. $2.57M consensus) primarily due to lower collaboration reimbursements. However, Diluted GAAP EPS of -$0.14 beat the -$0.16 consensus, aided by a $7.17M non-cash gain from the fair value change in warrant liabilities. Management provided a critical cash runway extension into 2029, supporting multiple clinical readouts for the IRD gene therapy pipeline through late 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Opus Genetics(IRD) the Revenue is 755 K (-73.8%), Miss estimate;the EBIT is -16.48 M (-85.04%), Miss estimate;the EPS is -0.08 (+33.33%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B73.80%
0.00B10.96%
-0.00B62.84%
EBITMiss expectations
-0.02B85.04%
-0.01B57.10%
-0.00B27.94%
EPSExceed expectations
-0.0833.33%
-0.156730.56%
+0.076763.89%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf